Pelvic-Floor Botox Finally Gets a Playbook

What the New AUGS Delphi Consensus Means — and Why ESSI Has Been Doing This All Along

A clinical commentary by the ESSI surgical team

Why This Paper Matters

For the women we see every week at ESSI—patients with endometriosis, adenomyosis, deep infiltrating disease, a long history of failed treatments, and pelvic pain that has outlived every hormonal, surgical, and physical-therapy attempt to control it—there is one finding that almost nobody talks about at first visit, but that virtually every one of them has: high-tone pelvic floor dysfunction (HTPFD).

Studies suggest that up to 80 percent of women with chronic pelvic pain have a myofascial component. The pelvic floor, irritated for years by deep endometriosis, adenomyosis, bladder inflammation, or simple guarding against pain, stops letting go. The muscles stay on. Trigger points build. Intercourse becomes painful. Urination becomes urgent. Bowel movements become a daily negotiation. Excision surgery can remove the disease—but if the muscle layer is left untreated, a substantial fraction of women still hurt on the other side of the operation.

That is precisely where pelvic-floor botulinum toxin A (BTA) injections come in. And until this year, there was no consensus on how to actually use them.

In March 2026, the American Urogynecologic Society (AUGS) published “Modified Delphi Consensus Guidelines for Pelvic Floor Botulinum Toxin Injection” (Hufnagel, Torosis, and Ackerman, Urogynecology 2026;32(4):312–320), the first structured, expert-driven attempt to define who should get pelvic Botox, how much, where, how often, and what to tell patients beforehand.

It is, in our view, an overdue and important document—and it validates a lot of what we’ve been doing at ESSI for years. This post walks through what the consensus actually says, why the biology supports it, and how we at ESSI integrate it into excision surgery.

What the Consensus Actually Did

The authors—based at UCLA’s Division of Urogynecology and Reconstructive Pelvic Surgery—used a modified Delphi method, which is the standard way to build expert consensus when randomized level-I evidence is thin. That’s exactly the situation with pelvic-floor Botox: we have small RCTs, meta-analyses with modest numbers, and a lot of off-label practice, but no large, uniform trial that answers the practical questions clinicians face.

The methodology, briefly:

• 46 potential experts were identified; eighteen agreed to participate.

• Three survey rounds were conducted.

• The panel was predominantly OB/GYN-trained, with sub-specialization in urogynecology or minimally invasive gynecologic surgery, plus one urologist.

• The median provider had performed 30 pelvic-floor Botox cases in the prior six months—these are high-volume injectors, not occasional dabblers.

Source: Hufnagel DH, Torosis M, Ackerman AL. Urogynecology (Phila) 2026;32(4):312-320.

 

The panel then generated a final consensus table covering five practical domains: patient selection, pre-procedure workup and counseling, technique, dosing, and follow-up.

The Key Themes That Reached Consensus

• On patient selection: The panel agreed that pelvic-floor BTA is appropriate for refractory myofascial pelvic pain—patients with documented pelvic floor tenderness or hypertonicity on exam who have tried and failed first-line therapies such as pelvic floor physical therapy, oral muscle relaxants, trigger-point injections with local anesthetic, and behavioral measures. It is a second- or third-line tool.

• On counseling: Patients need to be told that this is off-label in most jurisdictions, that onset is gradual (typically 1–2 weeks), that the effect is temporary (generally 3–6 months), and that transient side effects can occur. Pelvic-floor physical therapy should be continued during the Botox window, because the point isn’t to paralyze the floor: it is to open a window in which the patient can actually re-learn how to relax and recruit those muscles normally.

• On technique: The panel converged around targeted injection into the levator ani complex and obturator internus, guided primarily by palpation of the tender muscle or trigger point. Digital palpation by an experienced clinician is the backbone of site identification.

• On dosing: The consensus reinforces a moderate-dose, multi-site approach in a typical case (e.g., 20–30 units per injection site) rather than a single high-volume bolus.

• On re-injection: Consensus supported waiting a minimum of approximately 3 months between injections, typically re-treating at roughly 4–6 month intervals based on symptom return, and combining injections with ongoing PT.

(Note: Some questions remained unsettled, such as the precise upper dosing ceiling and the use of combined sedation versus office-based awake injection, which is exactly why high-volume surgical experience matters.)

The Biological Logic: Why This Therapy Makes Sense

BTA’s reputation as a cosmetic agent has obscured how sophisticated a drug it is. In a hypertonic pelvic floor, three mechanisms matter:

 

It blocks acetylcholine release at the neuromuscular junction (motor effect), and it reduces release of pain-signaling neuropeptides from peripheral nociceptors (sensory effect).

 

1. Neuromuscular blockade: BTA cleaves SNAP-25 at the neuromuscular junction, preventing acetylcholine release. The muscle relaxes. In a chronically contracted pelvic floor, this is the therapeutic effect patients feel first: the vice grip lets go.

2. Afferent (sensory) modulation: BTA also reduces release of pain-signaling neuropeptides—substance P, CGRP, glutamate—from peripheral nociceptors. This is why patients often report pain relief disproportionate to what simple muscle relaxation would predict. It is an analgesic effect on the peripheral nervous system.

3. Breaking the pain-spasm-pain cycle: Chronic pelvic pain generates guarding. Guarding produces hypertonicity. Hypertonicity produces ischemia, trigger points, and more pain, which generates more guarding. At some point the loop becomes self-sustaining and survives even after the original pain generator—the endometriosis or adenomyosis—is addressed.

Botox, combined with physical therapy, interrupts the loop long enough for normal muscle function to re-establish.

This third point is the one we think matters most in endometriosis patients specifically. Excision treats the disease. Botox, combined with physical therapy, treats the learned muscular response to the disease. One without the other is an incomplete operation in the subset of patients who have both.

How ESSI Uses Pelvic-Floor Botox

We have been incorporating pelvic-floor BTA into our practice for years, because the clinical signal was unmistakable in the right patient. The new AUGS document largely mirrors our internal protocol.

Botox is not a first-line tool. It is reserved for patients who have failed conservative therapy.

 

• Who we offer it to: We consider pelvic-floor Botox for any patient who, on preoperative exam, has clear pelvic floor hypertonicity or reproducible trigger points—especially when the clinical history includes deep dyspareunia persisting after prior excision, levator myalgia, vaginismus, urinary urgency with a normal bladder workup, anorectal pain, or a strong history of failed pelvic-floor PT.

• When we do it: In selected patients, we perform pelvic-floor Botox injections at the time of excision surgery, under the same anesthetic. This has several practical advantages: one recovery, one anesthesia exposure, full muscle relaxation during injection, and the ability to examine the entire pelvic floor carefully under anesthesia while planning excision.

• How we do it: Our standard is targeted injection into the levator ani complex and obturator internus, guided by palpation. We always couple the procedure with a structured post-operative pelvic-floor physical therapy plan. Botox without PT gives you a shorter, less durable result.

• What we tell patients: Off-label. Onset at roughly two weeks. Peak effect at four to six weeks. Duration three to six months. The goal is not to chase Botox forever—it is to use a 3-to-6-month window of relaxation to retrain the pelvic floor and break the cycle permanently.

A Conversation Between Drs. Vidali, Fernandez, and Bagaria

A discussion of the AUGS consensus and its implications by the ESSI surgical team. As always, clinical decisions should be individualized.

Dr. Vidali: I want to start by acknowledging what this paper really is. It is not groundbreaking science—it’s a consensus document. But it is the first time a major society has put in writing what high-volume clinicians have been saying for years: that pelvic-floor Botox has a legitimate, defined role in refractory myofascial pelvic pain, and that we now have a framework for who gets it, how much, and when. For the endometriosis world specifically, I think it validates something we’ve argued for a long time—that you cannot excise your way out of every pelvic pain problem. The muscle layer is a separate compartment, and it often needs its own treatment.

Dr. Fernandez: Agreed. And I’d go a step further. In my practice, the patients who come to me for re-operative excision—the second, third, even fourth surgery—are overwhelmingly patients in whom the pelvic floor was never addressed the first time. We remove residual disease and, yes, that matters. But if we don’t address the muscular component at the same time, we are setting some of these women up to come back.

Dr. Bagaria: That matches what I see as well. One of the things I appreciate about the AUGS document is that it insists on patient selection and failed conservative therapy first. Botox is not the opening move. Pelvic-floor physical therapy is the opening move. What Botox does in the right patient is unlock a window of relaxation so that physical therapy can actually work. I have patients who tried PT for a year and couldn’t tolerate it because the muscle was simply too guarded. After one Botox cycle, those same patients are able to do the therapy, and a subset of them never need a second Botox round.

Dr. Vidali: That’s the point I make to every patient. Botox is a tool, not a treatment plan. The treatment plan is: excise the disease, relax the muscle, retrain the muscle, manage the nervous system. Excision without Botox fails some patients. Botox without PT fails most patients. Botox without excision—in a woman who actually has endometriosis—is pure symptom management. You need the whole construct.

Dr. Fernandez: I also want to note something the consensus is careful about, which is counseling. A lot of patients come in having read about Botox online and expecting a miracle. The data is good for the right patient, but the response rate is not 100 percent, the effect is temporary, and there are side effects. The goal is not lifetime Botox dependence. The goal is to use the window.

Dr. Bagaria: One thing I’d add that I don’t think the consensus emphasized enough: the combination with surgery matters in how you dose. When we do injections at the time of excision, the patient is fully relaxed under anesthesia, you can examine every muscle group carefully, and you can target the specific bellies that reproduce pain on preoperative exam. That’s very different from an office injection in an awake patient.

Dr. Vidali: Right. And this is where experience really matters. A clinician doing 30 of these in six months—which was the panel’s median—has developed a feel for the muscle that a clinician doing three a year has not. The consensus gives us a framework, but the framework doesn’t inject the muscle. The surgeon does.

Dr. Fernandez: Last point from me: I think this paper is going to open doors for patients. A lot of generalist gynecologists have been hesitant to refer for pelvic-floor Botox because there was no society-level guidance. Now there is. I expect more appropriate referrals, earlier referrals, and honestly, fewer patients who have gone through five years of misery before anyone offers them this option.

Dr. Bagaria: And fewer patients who are told their pain is psychosomatic because their MRI looks clean. A tight pelvic floor does not show up on an MRI. A myofascial trigger point does not show up on ultrasound. This consensus says, clearly, that there is something wrong—and that we know how to treat it.

Dr. Vidali: Which is the whole reason ESSI exists. We’ll keep doing what we’ve been doing—excision, Botox in the right patient, pelvic-floor PT, multidisciplinary follow-up—and it’s good to see the literature catching up to the practice.

The Bottom Line

The AUGS/Hufnagel consensus is not a randomized trial. What it is, is the first formal, society-level acknowledgement that pelvic-floor Botox has a defined place in the care of women with refractory myofascial pelvic pain, and the first attempt to codify how to do it well.

For the endometriosis population specifically—where myofascial pain lives on top of, and sometimes persists after, the underlying disease is treated—this matters. Excision alone is not always enough. Physical therapy alone is not always enough. In the right patient, pelvic-floor Botox combined with excision and structured physical therapy is, in our experience, the most reliable path to durable relief.

If you have had multiple surgeries and still hurt, if physical therapy has been intolerable, if intercourse is still painful, if urinary urgency has no identifiable cause—ask whether your pelvic floor has been properly evaluated and properly treated. A muscle problem needs a muscle treatment.

This article reflects the clinical opinions of the ESSI surgical team and is not intended as medical advice. Use of botulinum toxin A for pelvic-floor myofascial pain is considered off-label in most jurisdictions. Patients should discuss risks, benefits, and alternatives with their own physician before pursuing treatment.

Reference

• Hufnagel DH, Torosis M, Ackerman AL. Modified Delphi Consensus Guidelines for Pelvic Floor Botulinum Toxin Injection. Urogynecology (Phila). 2026;32(4):312–320. doi:10.1097/SPV.0000000000001841. Open access via PubMed Central: PMC12994899.